MedKoo Cat#: 563110 | Name: SW43 HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SW43 is a synthetic ligand with high selectivity and affinity for the sigma-2 receptor (σ₂R), a receptor associated with cellular proliferation and implicated in cancer and neurodegenerative disease pathology. In binding assays, SW43 exhibits a Ki of approximately 13 nM for σ₂R, with significantly lower affinity for sigma-1 receptors (σ₁R), typically with a Ki >1 µM, demonstrating strong selectivity. Functional studies have shown that SW43 can induce cytotoxicity in various cancer cell lines, including pancreatic and breast cancer models, with IC₅₀ values in the low micromolar range (1–5 µM), suggesting potential for anti-tumor activity through σ₂R-mediated mechanisms, such as mitochondrial disruption, apoptosis, and autophagy induction.

Chemical Structure

SW43 HCl
SW43 HCl
CAS#SW43 HCl

Theoretical Analysis

MedKoo Cat#: 563110

Name: SW43 HCl

CAS#: SW43 HCl

Chemical Formula: C27H47Cl2N3O4

Exact Mass: 475.3410

Molecular Weight: 548.59

Elemental Analysis: C, 59.11; H, 8.64; Cl, 12.92; N, 7.66; O, 11.67

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Synonym
SW43; SW-43; SW 43; SW43 HCl; SW43 hydrochloride; SW43 dihydrochloride;
IUPAC/Chemical Name
(2,5-Dimethoxy-phenyl)-carbamic acid 9-(10-amino-decyl)-9-aza-bicyclo[3.3.1]non-3-yl ester dihydrochloride
InChi Key
HTPYAURXVGGRLN-UHFFFAOYSA-N
InChi Code
InChI=1S/C27H45N3O4.2ClH/c1-32-23-14-15-26(33-2)25(20-23)29-27(31)34-24-18-21-12-11-13-22(19-24)30(21)17-10-8-6-4-3-5-7-9-16-28;;/h14-15,20-22,24H,3-13,16-19,28H2,1-2H3,(H,29,31);2*1H
SMILES Code
O=C(OC1CC(N2CCCCCCCCCCN)CCCC2C1)NC3=CC(OC)=CC=C3OC.[H]Cl.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 548.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ludwig JM, Xing M, Gai Y, Sun L, Zeng D, Kim HS. Targeted Yttrium 89-Doxorubicin Drug-Eluting Bead-A Safety and Feasibility Pilot Study in a Rabbit Liver Cancer Model. Mol Pharm. 2017 Aug 7;14(8):2824-2830. doi: 10.1021/acs.molpharmaceut.7b00336. Epub 2017 Jul 25. PubMed PMID: 28700244. 2: McDonald ES, Mankoff J, Makvandi M, Chu W, Chu Y, Mach RH, Zeng C. Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells. Biochem Biophys Res Commun. 2017 May 6;486(3):788-795. doi: 10.1016/j.bbrc.2017.03.122. Epub 2017 Mar 24. PubMed PMID: 28347815. 3: Ludwig JM, Gai Y, Sun L, Xiang G, Zeng D, Kim HS. SW43-DOX ± loading onto drug-eluting bead, a potential new targeted drug delivery platform for systemic and locoregional cancer treatment - An in vitro evaluation. Mol Oncol. 2016 Aug;10(7):1133-45. doi: 10.1016/j.molonc.2016.05.003. Epub 2016 May 21. PubMed PMID: 27262893; PubMed Central PMCID: PMC4972658. 4: Hashim YM, Spitzer D, Vangveravong S, Hornick MC, Garg G, Hornick JR, Goedegebuure P, Mach RH, Hawkins WG. Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134. Mol Oncol. 2014 Jul;8(5):956-67. doi: 10.1016/j.molonc.2014.03.005. Epub 2014 Mar 26. PubMed PMID: 24731702; PubMed Central PMCID: PMC4082741. 5: Garg G, Vangveravong S, Zeng C, Collins L, Hornick M, Hashim Y, Piwnica-Worms D, Powell MA, Mutch DG, Mach RH, Hawkins WG, Spitzer D. Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer. Mol Cancer. 2014 Mar 7;13:50. doi: 10.1186/1476-4598-13-50. PubMed PMID: 24602489; PubMed Central PMCID: PMC4015918. 6: Hornick JR, Vangveravong S, Spitzer D, Abate C, Berardi F, Goedegebuure P, Mach RH, Hawkins WG. Lysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic cancer. J Exp Clin Cancer Res. 2012 May 2;31:41. doi: 10.1186/1756-9966-31-41. PubMed PMID: 22551149; PubMed Central PMCID: PMC3414770. 7: Hornick JR, Xu J, Vangveravong S, Tu Z, Mitchem JB, Spitzer D, Goedegebuure P, Mach RH, Hawkins WG. The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine. Mol Cancer. 2010 Nov 22;9:298. doi: 10.1186/1476-4598-9-298. PubMed PMID: 21092190; PubMed Central PMCID: PMC3106998.